Related Experiment Video
Updated: Dec 17, 2025
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration
Kazuo Umezawa1, Andrzej Breborowicz2, Shamil Gantsev3
1Department of Molecular Target Medicine, Aichi Medical UniversityNagakuteJapan.
Abstract:
There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF-κB inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF-κB components. Until now, DHMEQ has been used by many scientists in the world to suppress animal models of cancer and inflammation. Especially, it was shown to suppress difficult cancer models, such as hormone-insensitive breast cancer and prostate cancer, cholangiocarcinoma, and multiple myeloma. No toxicity has been reported so far. DHMEQ was administered via the intraperitoneal (IP) route in most of the animal experiments because of its simplicity. In the course of developmental studies, it was found that IP administration never increased the blood concentration of DHMEQ because of the instability of DHMEQ in the blood. It is suggested that inflammatory cells in the peritoneal cavity would be important for cancer progression, and that IP administration, itself, is important for the effectiveness and safety of DHMEQ. In the present review, we describe mechanism of action, its in vivo anticancer activity, and future clinical use of DHMEQ IP therapy.
Insights
Dehydroxymethylepoxyquinomicin (DHMEQ) effectively suppresses difficult cancers in animal models by inhibiting NF-κB. Intraperitoneal administration is key to its efficacy and safety, suggesting potential for clinical use.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Advances in cancer and leukemia therapy remain limited for aggressive and difficult-to-treat neoplastic diseases.
- Dehydroxymethylepoxyquinomicin (DHMEQ), an NF-κB inhibitor, was developed in 2000 based on epoxyquinomicin.
- DHMEQ specifically targets and inactivates NF-κB components, showing promise in preclinical studies.
Purpose of the Study:
- To review the mechanism of action of DHMEQ.
- To summarize its in vivo anticancer activity in various cancer models.
- To discuss the potential future clinical applications of DHMEQ via intraperitoneal (IP) therapy.
Main Methods:
- Review of existing scientific literature on DHMEQ.
- Analysis of DHMEQ's mechanism targeting NF-κB.
- Evaluation of in vivo anticancer data from animal models, focusing on IP administration.
Main Results:
- DHMEQ has demonstrated efficacy in suppressing challenging cancer models, including hormone-insensitive breast and prostate cancers, cholangiocarcinoma, and multiple myeloma.
- No significant toxicity has been reported for DHMEQ in preclinical studies.
- Intraperitoneal (IP) administration of DHMEQ, despite initial concerns about blood stability, appears crucial for its effectiveness and safety, potentially due to interactions within the peritoneal cavity.
Conclusions:
- DHMEQ is a potent NF-κB inhibitor with significant potential for treating aggressive cancers.
- Intraperitoneal administration is a critical factor for DHMEQ's therapeutic success and safety profile.
- Further clinical investigation of DHMEQ IP therapy is warranted for difficult-to-treat neoplastic diseases.
